GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » Dividend-Payout-to-FFO

Pharvaris NV (FRA:9EN) Dividend-Payout-to-FFO


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Pharvaris NV Business Description

Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.